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Polypharmacy, defined as taking five or more drugs, is inadequate in the cardiovascular setting 
ABSTRACT 
Background: By how much polypharmacy (defined by number of drugss) differs from polyactive 
ingredient use (defined by the number of pharmacologically active ingredients) has not been assessed. 
Objectives: to compare the extent of polypharmacy vs. polyactive ingredients among patients taking 
CV medicines. 
Methods: Prospective, 10-year follow-up study conducted among 880 participants of the CoLaus study 
taking CV drugs at baseline. Polypharmacy was defined as the use of 5 or more CV medicines; 
polyactive ingredient use was defined as the use of 5 or more pharmacologically active CV ingredients. 
Results: The prevalence of polypharmacy increased from 1.4% (0.7 - 2.4) [prevalence rate and (95% 
confidence interval)] at baseline to 11.9% (9.9 - 14.3) at follow-up, and the prevalence of polyactive 
ingredients increased from 2.4% (1.5 - 3.6) at baseline to almost 17.6% (15.2 - 20.3) at follow-up. The 
prevalence of combination drugs increased from 15.7% (13.3 - 18.3) at baseline to 25.9% (23 - 28.9) 
at follow-up, and the prevalence of 3-component combination use increased from 0.1% (0.0 - 0.6) at 
baseline to 2.3% (1.4 - 3.5)at follow-up.  At baseline, 9/21 participants on polyactive ingredients were 
not considered as being on polypharmacy; at follow-up, the rate was 50/155 participants. 
Conclusion: Among individuals taking CV drugs, polypharmacy as defined by the number of drugs 
underestimates the prevalence of individuals taking five or more pharmacologically active drugs. 
Polypharmacy should no longer be based on the number of drugs but on the number of 
pharmacologically active drugs. 
Keywords: polypharmacy; epidemiology; prevalence; prospective study; pharmacoepidemiology 
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INTRODUCTION  
Population aging is associated with an increased frequency of multimorbidity and evidence-
based guidelines recommend using several drugs in the treatment of a single condition. Both 
phenomena have made medication therapy particularly challenging as a growing number of patients 
take several drugs, which is referred to as polypharmacy (1-3).  
Although the term polypharmacy has been used for decades, a precise definition is lacking. 
The cut off points, methods and settings for exploring polypharmacy vary widely (4, 5). Most studies 
used a cut-off point of five or more drugs to define polypharmacy (6, 7). A definition based on the 
number of units or of pharmacologically active ingredients remains an open debate. Indeed, the 
emergence of drugs combining two or more pharmacologically active ingredients (e.g. polypill for 
cardiovascular diseases (CVDs) prevention) might change the concept of polypharmacy. By how much 
polypharmacy (defined by number of drugs) differs from polyactive ingredients (defined by the 
number of pharmacologically active ingredients) has not been assessed. 
Thus, this study aimed to compare the prevalence and 10-year trends of polypharmacy vs. 
polyactive ingredients among community-dwelling subjects taking CV medicines. 
METHODS  
Study population and design 
The Colaus study is an ongoing prospective survey investigating the biological and genetic 
determinants of cardiovascular risk factors and CVD in the population of Lausanne, Switzerland. 
Detailed descriptions of the study design have been reported elsewhere (8). A simple, non-stratified 
random sample of the Lausanne population aged 35-75 years was drawn. Recruitment began in June 
2003 and ended in May 2006 and included 6733 participants, with a participation rate of 41%. The 
follow-up was conducted 10.7 years on average after the collection of baseline data (May 2014-July 
2016).  
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Polypharmacy and polyactive ingredients 
Participants indicated which medicines, prescribed or obtained over-the-counter (OTC) they 
were currently taking. Medicines were coded according to the Anatomical Therapeutics Chemical 
(ATC) Classification System of the World Health Organization. For this study, only CV drugs were 
considered, i.e. all drugs belonging to ATC category “C” (cardiovascular system). 
The number of medicines was computed as the number of different drugs taken by the 
participant. Polypharmacy was defined as taking 5 or more CV drugs, including OTC drugs. The number 
of pharmacologically active ingredients was computed considering ATC codes corresponding to 
combinations (supplementary table 1). “Polyactive ingredient” was defined similarly to 
polypharmacy, i.e. 5 or more pharmacologically active CV ingredients. “CV drug combinations are 
defined as CV medicines combining at least two different active substances in the same product.” 
Exclusion criteria 
Participants were excluded if (i) they did not participate in the follow-up; (ii) they lacked 
information regarding CV medicines at baseline. 
Statistical analysis 
Statistical analysis was performed using Stata software version 14.2 (Stata Corp, College 
Station, TX, USA). Descriptive results were expressed as number of participants (percentage) for 
categorical variables and as average ± standard deviation or as median [interquartile range] for 
continuous variables. Between-group comparisons were performed using chi-square for categorical 
variables and student’s t-test or Kruskal-Wallis for continuous variables. Prevalences were expressed 
as percentage and [95% confidence interval]. Between-survey comparisons were performed using 
Cochran test for categorical data and Wilcoxon matched-pairs signed-ranks test for continuous data. 
Statistical significance was considered for a two-side test with p<0.05. 
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RESULTS 
Participants 
Of the 1332  participants eligible for the study (taking CV drugs), 880 (66.0%, 441 men) were 
included (figure 1). Included participants were younger, more frequently born in Switzerland and had 
a higher prevalence of former smokers, while no differences were found regarding gender or alcohol 
consumption Supplemental table 2. 
Trends in prevalence of polypharmacy, polyactive ingredient and cardiovascular drug combinations  
The trends in the number of drugs, pharmacologically active ingredients, and prevalence of 
polypharmacy, polyactive ingredient use and CV drug combinations at baseline and after 10 years 
follow-up are summarized in table 1. The prevalence of polypharmacy increased from 1.4% at baseline 
to almost 12% at follow-up; the prevalence of polyactive ingredients increased from 2.4% at baseline 
to almost 18% at follow-up, and the prevalence of combination drugs increased from 15.7% at baseline 
to almost 26% at follow-up. Finally, the prevalence of 3-component combination increased from 0.1% 
at baseline to 2.3% at follow-up. At baseline, the 95% confidence intervals for polypharmacy and for 
polyactive ingredient use overlapped, while at follow-up it was no longer the case. While the median 
of drug use doubled at follow up, the median of active ingredients tripled during the same period 
(table 1). 
At baseline, of the 21 participants on polyactive ingredients, 9 (43%) were considered as not 
being on polypharmacy, while at follow-up, of the 155 participants on polyactive ingredients, 50 (32%) 
were considered as not being on polypharmacy. 
DISCUSSION 
In ten years, the prevalence of both polypharmacy and polyactive ingredient increased among 
community-dwelling CV patients. If at baseline the prevalences of polypharmacy and polyactive 
ingredient were rather close, ten years afterwards the prevalence of polyactive ingredient was 
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significantly higher than the prevalence of polypharmacy. Further, at follow-up, a significant number 
of participants taking 5 or more pharmacologically active drugs was not considered as being on 
polypharmacy. 
“The issue of multidrug medications in cardiovascular treatment is complex. On one side, by 
reducing the number of drugs to be taken by the patients, cost could be reduced (9). Also, non-
compliance is higher in patients taking multiple antihypertensive drugs (10); hence, multidrug 
medications could be a simple and efficient method to reduce non-compliance and improve treatment 
efficiency (11, 12). On the other side, the fixed dose combinations reduce personalization of treatment 
and might complicate medication reviews if the name of the product is not provided.” 
By counting only the unit of CV drugs, those taking the combination of CV drugs are ignored. 
A study assessing polypharmacy in the US also mentioned that defining polypharmacy by drug 
ingredient may be the most biologically plausible approach (13). This issue is particularly important 
with regard to CVDs due to the emergence of the combinations which are becoming more prevalent. 
Furthermore, not only the number of combinations increased during the study period, but also the 
combinations including more than two active ingredients increased; i.e. even if the number of the unit 
of drugs stays steady, which it also increased here, still the number of active ingredients have been 
growing. Thus, polypharmacy as defined by the number of drugs may underestimate numbers of 
patients taking more than five active ingredients and cannot reflect the extent of the issue of 
polymedication. 
Limitations 
This study has several limitations worth acknowledging. First, all medicines were collected 
using self-reported data, which might be prone to information bias. However, a previous study showed 
that self-reported medication use closely relates with pharmacy records (14).  
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Conclusion 
Among individuals taking CV drugs, polypharmacy as defined by the number of drugs 
underestimates the prevalence of individuals taking five or more pharmacologically active ingredients. 
Polypharmacy should be counted as the number of pharmacologically active ingredient.  
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FIGURE LEGENDS 
Figure 1: selection procedure of the participants, CoLaus study, Lausanne, Switzerland. 
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TABLES 
Table 1: Trends in the prevalence of polypharmacy, polyactive ingredients and cardiovascular drug 
combination, CoLaus study, Lausanne, Switzerland 
 Baseline Follow-up 
Polypharmacy (%) 1.4 (0.7 - 2.4) 11.9 (9.9 - 14.3) 
Polyactive ingredient use (%) 2.4 (1.5 - 3.6) 17.6 (15.2 - 20.3) 
CV drug combination (%) 15.7 (13.3 - 18.3) 25.9 (23 - 28.9) 
Taking 3-component combinations (%) 0.1 (0.0 - 0.6) 2.3 (1.4 - 3.5) 
Number of cardiovascular   
Drugs 1 [1 - 2] 2 [1 - 3] 
Active ingredients 1 [1 - 2] 3 [1 - 4] 
CV, cardiovascular. Polypharmacy : 5 or more CV medicines; polyactive ingredient: 5 or more 
pharmacologically active CV ingredients. Results are expressed as percentage (95% confidence 
interval) or as median [interquartile range]. Between-survey comparisons were performed using 
Cochran test for categorical data and Wilcoxon matched-pairs signed-ranks test for continuous data. 
All comparisons are significant at p<0.001. “CV drug combinations are defined as CV medicines 
combining at least two different active substances in the same product.” 
 
 
